Novartis
East Hanover, New Jersey, 07936, United States
NCT Number: NCT00230074
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
Looking for future studies?
Notify Me21 year–80 year
All sexes
Interventional
Phase 2
East Hanover, New Jersey, 07936, United States
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined exclusion criteria may apply.
Novartis
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01925196
Amyotrophic Lateral Sclerosis, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05562960
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Taipei, Taiwan
View Trial DetailsNCT04259255
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT05189106
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Boston, Massachusetts, United States
View Trial Details